Abstract
Relevance. Sleeplessness is a non-motor disorder that reduces the daily activity of patients with Parkinson’s disease.Intention. To evaluate the effectiveness of the drug “Melaxen” (melatonin) in the treatment of patients with sleep disorders and daytime sleepiness in patients with Parkinson’s disease and previous radiation exposure.Methodology. Fifty patients with Parkinson’s disease (Stage I–II according to Hen-Yar, duration of 3.5 to 6.5 years), previous radiation exposure and current sleep disorders were examined. On average, patients aged (65.8 ± 5.8) years. Most of them were employees of various departments of the Russian Emercom and Defense Ministry. On average, 38 male patients spent (56.1 ± 27.0) days in the area of radiation exposure, with exposure dose of (21.4 ± 11.9) roentgen equivalent man (rem). Female patients-inhabitants of radiation contaminated areas most likely received mean effective dose of 9 mSv (0.9 rem) per person. During treatment of Parkinson’s disease with “Levodopa” in the average daily dosage of (562.5 ± 62.5) mg (stable dose after the start of melatonin), 39 (78 %) of them also received dopamine receptor agonists at a dose of (1.0 ± 0.25) mg / day, the drug Melaxen (melatonin) was used to correct sleep disordersfor over 28 days at a daily dose of 3 mg taken 30–40 minutes before sleep daily. The clinical and psychological state of the patients was studied twice before and after completion of the course of treatment using scales to study the quality and individual significance of sleep, the hospital anxiety and depression scale (HADS), certain cognitive tests and individual sleep diaries.Results and Discussion. According to the clinical and psychological tests, Melaxen (melatonin) contributed to improving the quality of sleep, mental well-being, activity, some cognitive functions, reducing daytime sleepiness and anxiety. The optimization of the mental state was also reflected in the personal diaries of sleep quality. A number of indicators only tended to improve, probably due to short-term studies.Conclusion. In patients with Parkinson’s disease, “Melaxen” was associaeted with improved sleep quality, decreased daytime sleepiness and severity of anxiety and depression, and also increased concentration.
Highlights
Нарушения сна у пациентов с болезнью ства ночных пробуждений и связанного с ним Паркинсона, ранее подвергшихся радиа двигательного беспокойства у пациентов ционному воздействию, усугубляют течение с болезнью Паркинсона, ранее подвергшихся основного заболевания и существенно ухуд радиационному воздействию, на фоне ком шают качество жизни больных, при этом для плексной терапии с использованием препа их коррекции на фоне лечения препаратами рата «Мелаксен» («Мелатонин»)
The report of the Committee without its annexes appears as Official Records of the General Assembly, Sixty-third Session, Supplement N 46. 2011. 220 р
Fifty patients with Parkinson’s disease (Stage I–II according to Hen-Yar, duration of 3.5 to 6.5 years), previous radiation exposure and current sleep disorders were examined
Summary
СОВРЕМЕННЫЕ МЕТОДЫ ЛЕЧЕНИЯ НАРУШЕНИЙ СНА ПРИ БОЛЕЗНИ ПАРКИНСОНА У ПАЦИЕНТОВ, РАНЕЕ ПОДВЕРГШИХСЯ РАДИАЦИОННОМУ ВОЗДЕЙСТВИЮ Недвигательными нарушениями, снижающими повседневную активность пациентов с болезнью Паркинсона, являются нарушения сна. Цель – оценить эффективность применения препарата «Мелаксен» («Мелатонин») в лечении пациен тов с нарушениями сна и дневной сонливости при болезни Паркинсона у больных, ранее подвергшихся радиационному воздействию.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
